Mr. Ma has more than 15 years of finance and operational expertise across pharmaceuticals and venture backed biotechnology companies. He most recently served as Director of Finance and Operations for Anwita Biosciences, Inc., a clinical stage company. Prior to that, he served as Sr. Director of Finance and Controller for Semnur Pharmaceuticals, a specialty pharmaceutical company focused on the clinical and commercial development of innovative products that meet the needs of pain management practitioners and their patients which was acquired by Scilex Holding Company in March 2019.  Prior to that, he served as Controller for Globavir and part of the management team that worked on the IPO process for the company.  He also served as the Controller for Ardelyx which went public in 2014. Prior to that, Mr. Ma served in various finance positions in PDL BioPharma and Hyperion Therapeutics.  Mr. Ma began his career with more than 10 years in high technology companies and has wealth of experience in finance, strategic planning, commercial launching, debt financing, public offerings, and M&A transactions.  Mr. Ma holds a B.S. in Finance and M.A. in Economics from San Jose State University.